Marshall Ma, D.V.M., Ph.D.

Biocytogen: Your preclinical CRO partner, from targets to therapeutics & one-stop solution from concept to IND Application Our Business: 1) BioMice for preclinical products (including gene editing services and off-the -shelf innovative animal and cell models) & pharmacology services; ● 🐁BioMice division offers a variety of products and services for preclinical research. - Off-the-shelf Animal Models - Preclinical Pharmacology Services - Gene Editing Services 2) RenBiologics for antibody therapeutics based on our fully human antibody & TCR platforms (RenMice). ● 💉RenBiologics division focuses on out-licensing fully human antibodies for therapeutic development to enrich your pipelines - Off-the-shelf Antibody Library - Preclinical PCC and Clinical Assets - Antibody Discovery Platform Licensing Our Vision: To be a leader in the development of new drugs and to revolutionize antibody therapeutic discovery. Our Missions: - Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research - Develop technological platforms to accelerate next-generation drug discovery and development - Empower scientists in drug discovery by providing the necessary expertise to eliminate bottlenecks in research - Be a global leader in providing seamless preclinical services to our clients BIOCYTOGEN（百奥赛图） 使命：专注技术创新 持续新药产出 守护人类健康 愿景：成为全球新药发源地

Led multi-color flow cytometry biomarker assay development and qualification/validation for immunophenotyping and quantification of immune cell therapy products (NK-cell), ensuring compliance with industry guidelines. - Developed and qualified cell-based assays for NK-cell drug products, facilitating characterization, stability testing, and GMP lot release for a phase I clinical trial. - Optimized potency assays to demonstrate mechanism of action for LNP-mRNA CAR-T and NK-cell therapy products. - Supervised timely in-process testing during cell therapy manufacturing, collaborating with cross-functional teams and ensuring method transfer to CDMOs. - Trained and mentored senior research associates in assay development, flow cytometer maintenance, GMP lot testing, and quality event investigations. Corporate Mission & Vision We envision a world where people take the lead in improving their healthcare outcomes and their lives. We are an innovative global healthcare company with one purpose: to chase the miracles of science to improve people’s lives.

Pioneered optimization strategies for induced pluripotent stem cells-derived NK cells (iPSC-NK), led diverse scale-up initiatives, enhanced process SOPs, established bioanalytical methods, and trained team members to boost productivity. - Optimized critical process parameters for iPSC-NK cells, enhancing product purity and yield using QbD and DoE approaches. - Scaled up NK cell production from various sources, adhering to cGMP regulations with feeder-dependent or feeder-free expansion platforms. - Established flow cytometry-based assays to assess the quality and potency of iPSCs and their differentiated cell products. - Trained and collaborated with scientists for effective teamwork, focusing on iPSC clone selection and HSC/NK differentiation optimization. Corporate Mission & Vision We empower Natural Killer cells to fight cancer through stem cell engineering and multispecific antibodies.

Developed high-titer, pure rAAV for modulating Gprc6a in Alzheimer's mouse models, employed intracranial stereotaxic surgery, and evaluated therapeutic effects for preclinical research. - Produced high-titer, pure rAAV for manipulating Gprc6a gene expression in preclinical AD tauopathy mouse models. - Conducted comprehensive translational rAAV gene therapy research from construction to in vivo injection and assessment. - Established a novel N2a-ssGT cell line measuring tau oligomerization, licensed for drug screening in AD and tauopathy diseases.

Directed the development and characterization of genetic reduction of myeloid cell Arg1 in preclinical AD mouse models, utilized leading targeted transcriptome profiling technology, and mentored several student researchers. - Developed and characterized a comprehensive assessment of myeloid cell Arg1 gene haploinsufficiency in preclinical AD mouse models. - Conducted targeted transcriptome profiling analysis using NanoString technology to evaluate myeloid cell Arg1 insufficiency in preclinical AD mouse brains. - Mentored a master graduate student into a senior laboratory technician and trained over five undergraduate volunteers pursuing medical careers.

Completed the assessment of NK cell therapy anti-cancer responses in preclinical immunodeficiency mouse models, including cell preparation, injection, detection, and data analysis for in vivo therapeutic evaluation. - Conducted in vivo experiments assessing PBNK cell efficacy in a xenograft mouse model of CNS-ALL, covering cell preparation, injection, isolation, detection, and data analysis. - Utilized in vivo ultrasound imaging to detect and quantify tumor size in immunodeficient mice with human primary ovarian cancer treated with iPSC-CAR-NK cells.

Led the research and characterization of human lymphocyte derived from various stem cell sources for in vitro disease modeling and potential therapeutic applications in immunodeficiency disorders. - Successfully generated and characterized human B, T, and NK cells from both umbilical cord blood and pluripotent stem cells (PSCs). - Established and validated in vitro models utilizing human PSC-derived T and NK cells for treating immunodeficient diseases like X-SCID and WAS.

Ma, Chao, "Impact of Arginine Metabolism and Sensing in Mouse Models of Alzheimer’s Disease" (2022). USF Tampa Graduate Theses and Dissertations. https://digitalcommons.usf.edu/etd/10325

Ma, Chao. (2014). Derivation of lymphocytes from human induced pluripotent stem cells. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/167296.

The Bachelor of Agriculture in Veterinary Medicine (five-year track) is the first professional degree in veterinary medicine (DVM) in China and entitles the holder to practice in the home country. (World Education Services)